Tirzepatide's effect on liver health in obese patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the impact of tirzepatide, a medication used for treating type 2 diabetes and obesity, on markers of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in patients with obesity. Participants will take tirzepatide for 12 months and attend clinic visits every three months, during which blood samples will be collected and liver ultrasounds performed. The study aims to determine how tirzepatide influences liver health in individuals diagnosed with MASLD.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Men and women
* Age 18-75
* Diagnosis of MASLD based on the following criteria:

  * Presence of at least 1 out of the 5 following cardiometabolic criteria:
* BMI \>25 kg/m2 OR waist circumference \>94 cm (men) or 80cm (women)
* Fasting serum glucose \>100 mg/dL OR 2-hour post-prandial glucose levels \>140mg/dL OR AbA1c \>5.7% OR type 2 diabetes OR treatment for type 2 diabetes
* Blood pressure \>130/85 mmHg OR specific antihypertensive drug treatment
* Plasma triglycerides \>150mg/dL OR on lipid lowering treatment
* Plasma HDL-cholesterol \<40mg/dL (men) and \<50mg/dL (women) OR on lipid lowering medication

  * No other identified causes of steatosis
  * Evidence of steatotic liver disease (hepatic steatosis identified by imaging or biopsy)
* English speaking

Exclusion Criteria:

* Pregnancy or breast feeding
* Premenopausal women not on any form of contraception
* Reports alcohol intake \>50g/day or 350g/week for women and \>60g/day or 420g/week for men or an AUDIT score \>8
* Other identifiable causes of steatosis
* Documented allergic reaction to tirzepatide or any other GLP1 RA
* Decompensated liver disease
* Decompensated renal disease requiring hemodialysis
* Decompensated heart failure
* Active malignancy
* Prior history of pancreatitis
* Serum triglyceride levels \>500 mg/dL
* Personal or family history of medullary thyroid cancer or MEN2a or MEN2b
* Concurrent use of other ant-obesity medications
* Use of other GLP1 RAs within 3 months of study enrollment
* Unable to obtain the medication due to cost or insurance coverage restrictions.

Where it's running

• University of New Mexico Health Sciences Center
  Albuquerque, New Mexico, United States Recruiting

Study contacts

• Principal investigator: Eliseo Castillo — UNM Cancer Center
• Study coordinator: Kristen Gonzales, MD
• Email: KrGonzales@salud.unm.edu
• Phone: 15052723840

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Effects of a high fructose diet on gut health and metabolism

  This study is testing how eating a high fructose diet affects gut health and metabolism in people who may struggle to digest fructose.

  Recruiting Icahn School of Medicine at Mount Sinai · New York, New York · NCT06329544

• Endoscopic sleeve gastroplasty for people with obesity and MASH

  This study will test whether endoscopic sleeve gastroplasty plus lifestyle changes helps adults with obesity and MASH lose weight and improve liver health compared with lifestyle changes alone.

  Recruiting at 2 sites Brigham and Women's Hospital · Boston, Massachusetts and 1 other locations · NCT06138821

• Screening patients at risk for liver disease in Europe

  This study is trying to find out if screening high-risk patients in Europe for liver disease using simple tests can help doctors identify and better understand conditions like metabolic dysfunction-associated steatotic liver disease.

  Recruiting at 6 sites Julius Clinical · Brussels, Vlaams-brabant and 12 other locations · NCT05651724

• Ocular Changes in People Using Tirzepatide or Semaglutide

  This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.

  Recruiting Istanbul University · Istanbul, Istanbul · NCT07924618

• Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

  This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.

  Recruiting Pamukkale University · Denizli · NCT07924436

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.